

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

Vivli

RRID:SCR_018080

Type: Tool

Proper Citation

Vivli (RRID:SCR_018080)

Resource Information

URL: <https://vivli.org/>

Proper Citation: Vivli (RRID:SCR_018080)

Description: Independent, non-profit organization that has developed global data-sharing and analytics platform to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through creation and implementation of sustainable global data-sharing enterprise. Our focus is on sharing individual participant-level data from completed clinical trials. Users can search listed studies, request data sets from data contributors, aggregate data, or share data of their own. Vivli (Center for Clinical Research Data) is launching a portal to share participant-level data from COVID trials.

Resource Type: data or information resource, nonprofit organization, service resource

Keywords: Global data sharing, clinical research data, data, sharing, analytical platform, clinical trial, COVID-19-related trials

Related Condition: COVID-19

Funding: Doris Duke Charitable Foundation ;
Leona M. and Harry B. Helmsley Charitable Trust ;
Lyda Hill Philanthropies ;
Phrma

Availability: Restricted

Resource Name: Vivli

Resource ID: SCR_018080

Alternate IDs: DOI:10.17616/R3SB9S, DOI:10.25504/FAIRsharing.uovQrT,
DOI:10.25934, r3d100012823

Alternate URLs: <https://vivli.org/vivli-covid-19-portal-2/>, <https://doi.org/10.17616/R3SB9S>, <https://doi.org/10.17616/r3sb9s>, <https://doi.org/10.25934/>, <https://dx.doi.org/10.25934/>, <https://fairsharing.org/10.25504/FAIRsharing.uovQrT>, <https://doi.org/10.17616/R3SB9S>

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260821T194124+0000

Ratings and Alerts

No rating or validation information has been found for Vivli.

No alerts have been found for Vivli.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1934 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lau G, et al. (2026) Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial. Hepatology (Baltimore, Md.), 83(3), 484.

Chehade M, et al. (2026) Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis. The American journal of gastroenterology, 121(3), 649.

Gormley ME, et al. (2026) Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study. Developmental medicine and child neurology, 68(2), 227.

Ramanan AV, et al. (2026) Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis. Arthritis care & research, 78(4), 431.

Levis MJ, et al. (2026) FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood advances, 10(3), 917.

Wollenberg A, et al. (2026) Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials. Journal of the European Academy of Dermatology and Venereology : JEADV, 40(7), 1218.

Lee JS, et al. (2026) Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52. Cancer science, 117(4), 1124.

de la Rambelje MA, et al. (2026) Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD. *Diabetes, obesity & metabolism*, 28(1), 750.

Rudin CM, et al. (2026) Ifinatamab Deruxtecane in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDEATE-Lung01 Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 44(4), 261.

Giblin K, et al. (2026) Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. *Diabetes, obesity & metabolism*, 28(1), 83.

Kato M, et al. (2026) Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial. *Psychiatry and clinical neurosciences*, 80(1), 76.

Hall K, et al. (2026) Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States. *Blood advances*, 10(3), 682.

Lundahl A, et al. (2026) AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma. *British journal of clinical pharmacology*, 92(1), 257.

Patel K, et al. (2026) Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. *Blood advances*, 10(7), 2441.

Govindu S, et al. (2026) Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab. *Journal for immunotherapy of cancer*, 14(1).

DiMartino SJ, et al. (2026) A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip. *RMD open*, 12(1).

Silverberg JI, et al. (2026) Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADAPT Study. *Dermatology and therapy*, 16(2), 1309.

Yi S, et al. (2026) A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321. *British journal of haematology*, 208(3), 926.

Stander S, et al. (2026) A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". *Dermatology and therapy*, 16(2), 1433.

Lange R, et al. (2026) A real-world study to describe the effectiveness and usage patterns of hyoscine butylbromide plus tablets in patients with dysmenorrhoea. *Women's health (London, England)*, 22, 17455057251406956.